Syndax Pharmaceuticals
Revumenib, a menin inhibitor small molecule therapeutic for acute leukemia
- Sector
- Biotech
- Headquarters
- WALTHAM, MA
- Founded
- 2005
- Latest Form D
- $61.3M, Aug 2015
- Total capital
- $140M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $140M
- 9 Form D · last Aug 2015
- 134 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 34 pending · first 2022
- Rank in peer group#245 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 9th filing$61.3M
- Private capital raisedForm D · SEC · 8th filing$24M
- Private capital raisedForm D · SEC · 7th filing$4.9M
- Private capital raisedForm D · SEC · 6th filing$1.7M
- Private capital raisedForm D · SEC · 5th filing$1.3M
- Private capital raisedForm D · SEC · 4th filing$50K
- Private capital raisedForm D · SEC · 3rd filing$31.3M
- Private capital raisedForm D · SEC · 2nd filing$6M
- Private capital raisedForm D · SEC · 1st filing$9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Arlene MorrisExecutive Officer, DirectorNamed in SEC Form D filings
- Briggs W Morrison, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- Dennis PodlesakDirectorNamed in SEC Form D filings
- Fabrice EgrosDirectorNamed in SEC Form D filings
- Fabrice Egros, Ph.D.DirectorNamed in SEC Form D filings
- George W Sledge, Jr. M.D.DirectorNamed in SEC Form D filings
Show all 22 people
- George W Sledge, Jr., M.D.DirectorNamed in SEC Form D filings
- Henry W ChenDirectorNamed in SEC Form D filings
- Ivor RoystonDirectorNamed in SEC Form D filings
- Ivor Royston, M.D.DirectorNamed in SEC Form D filings
- Joanna Horobin, M.D.Director, Executive OfficerNamed in SEC Form D filings
- John PalliesExecutive OfficerNamed in SEC Form D filings
- Kim Kamdar, PhDDirectorNamed in SEC Form D filings
- Kim Kamdar, Ph.DDirectorNamed in SEC Form D filings
- Kim Kamdar, Ph.D.DirectorNamed in SEC Form D filings
- Luke Evnin, Ph.D.DirectorNamed in SEC Form D filings
- Michael W MetzgerExecutive OfficerNamed in SEC Form D filings
- Richard P SheaDirectorNamed in SEC Form D filings
- Robert Goodenow, PhDExecutive OfficerNamed in SEC Form D filings
- Robert Goodenow, Ph.D.Executive OfficerNamed in SEC Form D filings
- Rosina Maar Pavia, M.D.DirectorNamed in SEC Form D filings
- Steven St. Peter, M.D.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- PendingPyran And Cyclohexyl Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionUSPTOApplication 19553056
- PendingBenzamide Aryl Ether Analogs Comprising An Amine Linker As Inhibitors Of The Menin-mll InteractionUSPTOApplication 19553044
- PendingBenzamide Amine Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionUSPTOApplication 19410434
Show all 40 patent records
- Pyran And Cyclohexyl Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionSep 3, 2026 · Application 19553056Pending
- Benzamide Aryl Ether Analogs Comprising An Amine Linker As Inhibitors Of The Menin-mll InteractionSep 3, 2026 · Application 19553044Pending
- Benzamide Amine Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionJun 11, 2026 · Application 19410434Pending
- Combinations Of Menin Inhibitors And CYP3A4 Inhibitors And Methods Of Use ThereofJun 4, 2026 · Application 19458303Pending
- CSF-1R Antibodies For The Treatment Of Chronic Graft Versus Host DiseaseMay 14, 2026 · Application 19447470Pending
- Combinations Of Menin Inhibitors And CYP3A4 Inhibitors And Methods Of Use ThereofMar 3, 2026 · US 12,564,590Granted
- CSF-1R Antibodies For The Treatment Of Chronic Graft Versus Host DiseaseFeb 17, 2026 · US 12,552,869Granted
- Combination Therapy With An Anti-colony Stimulating Factor 1 Receptor Antibody And A Jak InhibitorOct 23, 2025 · Application 19185796Pending
- Menin-mll Inhibitors For The Treatment Of CancerSep 25, 2025 · Application 18863966Pending
- Salts And Polymorphic Forms Of Menin Inhibitors And Pharmaceutical Compositions ThereofMay 29, 2025 · Application 18935892Pending
- Method Of Treating Cancer Using A Combination Of Entinostat And An ANTI-CSF-1R AntibodyFeb 27, 2025 · Application 18947814Pending
- Methods Of Treating Chronic Graft-versus-host Disease-related Bronchiolitis Obliterans Syndrome Using An Anti-colony Stimulating Factor 1 Receptor AntibodyJan 9, 2025 · Application 18666375Pending
- Method Of Treating Cancer Using A Combination Of Entinostat And An ANTI-CSF-1R AntibodyDec 17, 2024 · US 12,168,054Granted
- Combination Of Hdac Inhibitor And ANTI-PD-1 Antibody For Treatment Of CancerDec 5, 2024 · Application 18797933Pending
- Selection Of Patients For Combination TherapyAug 29, 2024 · Application 18648666Pending
- Selection Of Patients For Combination TherapyJun 4, 2024 · US 12,000,829Granted
- Selection Of Patients For Combination TherapyMar 2, 2023 · Application 17707081Pending
- Combination Of Hdac Inhibitor And ANTI-PD-1 Antibody For Treatment Of CancerJan 26, 2023 · Application 17716547Pending
- Selection Of Patients For Combination TherapyJul 26, 2022 · US 11,397,184Granted
- Combination Of Hdac Inhibitor And ANTI-PD-1 Antibody For Treatment Of CancerMay 10, 2022 · US 11,324,822Granted
- Methods For The Treatment Of Breast CancerNov 14, 2019 · Application 16248443Pending
- Combination Of Hdac Inhibitor And ANTI-PD-L1 Antibody For Treatment Of CancerDec 13, 2018 · Application 15739107Pending
- Administration Of An Inhibitor Of HdacNov 14, 2013 · Application 13940137Pending
- Methods For The Treatment Of Lung CancerJun 13, 2013 · Application 13708856Pending
- Salts And Polymorphic Forms Of Menin Inhibitors And Pharmaceutical Compositions ThereofApplication PCTUS2024054432Pending
- Pyran And Cyclohexyl Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionApplication PCTUS2026017169Pending
- Benzamide Aryl Ether Analogs Comprising A 4,5-SPIRO Ring System As Inhibitors Of The Menin-mll InteractionApplication PCTUS2026017160Pending
- Menin Inhibitors For The Treatment Of Myeloproliferative NeoplasmsApplication PCTUS2025050578Pending
- Benzamide Aryl Ether Analogs Comprising A Direct Link As Inhibitors Of The Menin-mll InteractionApplication PCTUS2026016998Pending
- Aryl Ether Analogs Comprising An Ether Link As Inhibitors Of The Menin-mll InteractionApplication PCTUS2026017175Pending
- Benzamide Aryl Ether Analogs Comprising An Amine Linker As Inhibitors Of The Menin-mll InteractionApplication PCTUS2026017166Pending
- Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionApplication 63620520Pending
- Combination Therapy With An Anti-colony Stimulating Factor 1 Receptor Antibody And A Jak InhibitorApplication 63637116Pending
- Sulfur-substituted Benzamide Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionApplication 63729130Pending
- Benzamide Amine Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionApplication 63914807Pending
- Benzamide Amine Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionApplication 63729167Pending
- Methods Of Treating Chronic Graft-versus-host Disease-related Bronchiolitis Obliterans Syndrome Using An Anti-colony Stimulating Factor 1 Receptor AntibodyApplication PCTUS2024029683Pending
- Prolinamide Inhibitors Of The Menin-mll InteractionApplication 63764164Pending
- Aryl Ether Analogs As Inhibitors Of The Menin-mll InteractionApplication 63651602Pending
- Combination Therapy With An Anti-colony Stimulating Factor 1 Receptor Antibody And A Jak InhibitorApplication 63749752Pending
Related companies, and why
- HotSpot TherapeuticsSimilar federal contract value in Biotech · null in contracts
- MICROPURE GENOMICS INCSimilar federal contract value in Biotech · null in contracts
- Lenz Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Inspirna, Inc.Similar federal contract value in Biotech · null in contracts
- ANOVAC, INC.Similar federal contract value in Biotech · null in contracts
- SATIETY INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .